N-((1-methyl-4,5-diphenyl-1H-imidazol-2-yl)methyl)aniline | 1443114-47-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-((1-methyl-4,5-diphenyl-1H-imidazol-2-yl)methyl)aniline
• CAS: 1443114-47-3
• 化学式: C₂₃H₂₁N₃
• 分子量: 339.44
• InChiKey: VXBROBJZOANZHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.37
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  29.85
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 N-((1-methyl-4,5-diphenyl-1H-imidazol-2-yl)methyl)aniline 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以89%的产率得到N-methyl-N-((1-methyl-4,5-diphenyl-1H-imidazol-2-yl)methyl)aniline
  参考文献：
  名称：

  Synthesis and Metabolic Studies of Host-Directed Inhibitors for Antiviral Therapy

  摘要：

  Targeting host cell factors required for virus replication provides an alternative to targeting pathogen components and represents a promising approach to develop broad-spectrum antiviral therapeutics. High-throughput screening (HTS) identified two classes of inhibitors (2 and 3) with broad-spectrum antiviral activity against ortho- and paramyxoviruses including influenza A virus (IAV), measles virus (MeV), respiratory syncytial virus (RSV), and human parainfluenza virus type 3 (HPIV3). Hit-to-lead optimization delivered inhibitor 28a, with EC50 values of 0.88 and 0.81 mu M against IAV strain WSN and MeV strain Edmonston, respectively. It was also found that compound 28a delivers good stability in human liver S9 fractions with a half-life of 165 min. These data establish 28a as a promising lead for antiviral therapy through a host-directed mechanism.

  DOI：

  10.1021/ml400166b
• 作为产物：
  描述：

  4,5-diphenyl-1-methyl-1H-imidazole 在 正丁基锂 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 2.75h， 生成 N-((1-methyl-4,5-diphenyl-1H-imidazol-2-yl)methyl)aniline
  参考文献：
  名称：

  Synthesis and Metabolic Studies of Host-Directed Inhibitors for Antiviral Therapy

  摘要：

  Targeting host cell factors required for virus replication provides an alternative to targeting pathogen components and represents a promising approach to develop broad-spectrum antiviral therapeutics. High-throughput screening (HTS) identified two classes of inhibitors (2 and 3) with broad-spectrum antiviral activity against ortho- and paramyxoviruses including influenza A virus (IAV), measles virus (MeV), respiratory syncytial virus (RSV), and human parainfluenza virus type 3 (HPIV3). Hit-to-lead optimization delivered inhibitor 28a, with EC50 values of 0.88 and 0.81 mu M against IAV strain WSN and MeV strain Edmonston, respectively. It was also found that compound 28a delivers good stability in human liver S9 fractions with a half-life of 165 min. These data establish 28a as a promising lead for antiviral therapy through a host-directed mechanism.

  DOI：

  10.1021/ml400166b